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Background: Previous pharmacokinetic trials suggested that 40 mg subcutaneous enoxaparin once daily provided
inadequate thromboprophylaxis for intensive care unit patients. Critically ill patients with acute kidney injury are at
increased risk of venous thromboembolism and yet are often excluded from these trials. We hypothesized that for
critically ill patients with acute kidney injury receiving continuous renal replacement therapy, a dose of 1 mg/kg
enoxaparin subcutaneously once daily would improve thromboprophylaxis without increasing the risk of bleeding.
In addition, we seek to utilize urine output prior to discontinuing dialysis, and low neutrophil gelatinase-associated
lipocalin in dialysis-free intervals, as markers of renal recovery.
Methods/Design: In a multicenter, double-blind randomized controlled trial in progress at three intensive care
units across Denmark, we randomly assign eligible critically ill adults with acute kidney injury into a treatment
(1 mg/kg enoxaparin subcutaneously once daily) or control arm (40 mg enoxaparin subcutaneously once daily)
upon commencement of continuous renal replacement therapy.
We calculated that with 133 patients in each group, the study would have 80% power to show a 40% reduction in
the relative risk of venous thromboembolism with 1 mg/kg enoxaparin, at a two-sided alpha level of 0.05. An
interim analysis will be conducted after the first 67 patients have been included in each group.
Enrolment began in March 2013, and will continue for two years. The primary outcome is the occurrence of venous
thromboembolism. Secondary outcomes include anti-factor Xa activity, bleeding, heparin-induced
thrombocytopenia, filter lifespan, length of stay, ventilator free days, and mortality. We will also monitor neutrophil
gelatinase-associated lipocalin and urine volume to determine whether they can be used as prognostic factors for
renal recovery.
Discussion: Critically ill unit patients with acute kidney injury present a particular challenge in the provision of
thromboprophylaxis. This study hopes to add to the growing evidence that the existing recommendation of 40 mg
enoxaparin is inadequate and that 1 mg/kg is both safe and effective for thromboprophylaxis.
In addition, the study seeks to identify predictors of renal recovery allowing for the proper utilization of resources.
Trial Registration: EU Clinical Trials Register: EudraCT number: 2012-004368-23, 25 September 2012.
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Approximately 30% of critically ill patients admitted to
an intensive care unit (ICU) develop acute kidney injury
(AKI) [1]. Biomarker neutrophil gelatinase-associated
lipocalin (NGAL) is associated with the development of
AKI, the need for dialysis, and mortality [1-4].
Despite ICU patients receiving recommended doses of
prophylactic low- molecular-weight heparin (LMWH),
between 5 and 15.5% develop proximal leg deep-vein
thrombosis (DVT) [5,6]. ICU patients with AKI fre-
quently have activated coagulation pathways triggered
by increased tissue factor and fibrinogen, reduced fi-
brinolysis, activation of endothelial surfaces, and throm-
bocytes. Thus such patients have a four-fold higher risk
for developing venous thromboembolism (VTE) com-
pared with ICU patients without renal insufficiency [7-9].
Critically ill patients with AKI are also predisposed to
bleeding because of uremic platelet dysfunction, coagu-
lopathies, and comorbidities. However many bleeding
episodes are deemed as minor [10,11].
Major or fatal bleeding is very rare in the ICU, whereas
VTE is relatively more common. VTE may not be de-
tected in the ICU patient population as the symptoms are
often minimal or atypical [12-14]. In many studies high-
dose enoxaparin yields high peak and trough anti-factor
Xa (anti-Xa) values, but no increase in bleeding compli-
cations regardless of the degree of renal insufficiency
[15]. A delay in starting thromboprophylaxis was associ-
ated with an increased risk of mortality in patients on
the ICU [16]. Thus, the risk-benefit ratio seems to favor
use of anticoagulant thromboprophylaxis [10].
In a recent study, we showed that a weight-based dose
of enoxaparin subcutaneous (sc) once daily (QD) contrary
to the standard dose of 40 mg enoxaparin sc QD yielded
satisfactory levels of anti-Xa for critically ill patients, was
more likely to maintain anti-Xa levels within the thera-
peutic range for longer periods of time and did not result
in bioaccumulation [17].
The primary objective of this study is to reduce the in-
cidence of VTE among AKI patients on continuous
renal replacement therapy (CRRT) by using 1 mg/kg
enoxaparin sc QD, versus the standard dose of 40 mg
enoxaparin sc QD. We hypothesized that higher doses of
enoxaparin would optimize thromboprophylaxis without
increasing the risk of bleeding in these patients. Secondary
objectives of the trial include examining the utility of neu-
trophil gelatinase-associated lipocalin (NGAL) levels and
urine output as predictors of renal recovery.
Methods/Design
Trial design
This is a multicenter randomized controlled trial con-
ducted at three ICUs across Denmark to assess whether
a dose of 1 mg/kg enoxaparin versus standard dose of40 mg enoxaparin will improve thromboprophylaxis in
AKI patients on CRRT, without increasing the risk of
bleeding. We will randomly assign eligible critically ill
adults with AKI into a treatment arm (1 mg/kg enoxa-
parin sc QD) or a control arm (40 mg enoxaparin sc QD)
upon commencement of CRRT. The sample population
will consist of 133 patients from ICUs at Odense Univer-
sity Hospital (OUH), Svendborg Hospital, and SVS Esbjerg
Hospital. An interim analysis will be conducted after
the first 67 patients have been included in each group.
Enrolment began in March 2013 and will continue until
March 2015. Patients will be followed until either: (1) a
combination of VTE and renal recovery, (2) a combination
of heparin - induced thrombocytopenia (HIT) and renal
recovery, (3) ICU death or discharge, or (4) change from
continuous to intermittent dialysis. Investigators will ob-
tain consent for the collection of data on treatments and
outcomes for participants who withdraw prematurely
from the project. Many of the current investigators have
participated in other trials and, as such, have a proven
track record with respect to enrolment and follow-up of
participants and collecting complete data sets. We will
document the reasons for missing data, collect auxiliary
variables that may predict outcome and/or determine
which patients are more susceptible to dropout, and
follow-up on all such patients until 24 hours after the
last dose of enoxaparin.
Ethics
Ethical approval for this protocol was obtained from the
Danish national scientific ethical committee (reference
number: 1210528) and the study was also approved by
Danish Health and Medicines Authority (reference
number: 2012100176) (see Tables 1 and 2). The study
will comply with the ethical principles set forth in the
Declaration of Helsinki and will be conducted in ac-
cordance with good clinical practice. Funding sources
for this research had no role in the design of this study
and will have no authority over data collection, analysis,
interpretation, or reporting of this study.
Research physicians on the ICUs of the aforementioned
three hospitals will obtain written informed consent
from all potential trial participants or their designated
surrogates for participation in the study. The partici-
pants will then be randomized following recruitment
and clinical interviews. For those who suffer harm from
trial participation, there is the possibility to appeal and
receive compensation according to the Act on the Right to
Complain and Receive Compensation within the Danish
health service. At the end of the trial, participants who in-
dicate on the consent form that they wish to be informed
of the results will be contacted by the trial sponsor. The
model consent form and other related documents given to
participants and designated surrogates are provided as
Table 1 World Health Organization trial registration data
set
Data category Information
Primary registry and trial
identifying number
EU clinical trials register:
EudraCT number: 2012-004368-23





Danish health and medicines authority:
2012100176
Danish national scientific ethical committee:
1210528 Sponsor's protocol number 20121005
Source(s) of monetary
or material support
Danish society of anesthesiology & intensive
medicine’s research initiative
Odense University Hospital’s research grant
Lippmann fund
Primary sponsor Palle Toft, Professor at the department of
Anesthesiology and Intensive Care at Odense




Sian Robinson, MB, BS; EDIC
Odense University Hospital
Department of Anesthesiology and Intensive
Care
Sdr. Boulevard 29. Odense C
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Email: sian.robinson@rsyd.dk
Public title A feasible strategy for preventing blood clots
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Scientific title A feasible strategy for preventing blood clots
in critically ill patients with acute kidney injury







Venous thromboembolism, enoxaparin dose,
acute kidney injury, bleeding
Intervention(s) Treatment arm: 1 mg/kg enoxaparin
subcutaneous once daily
Control arm: 40 mg enoxaparin subcutaneous
once daily
Enoxaparin will be administered
subcutaneously to the thigh or abdomen of the
study patients from the day of inclusion, until
the end of each participant’s study period.




Inclusion criteria: patients are eligible if they
give consent, develop acute kidney injury,
need continuous renal replacement therapy,
weigh 45 to 150 kg, and are ≥18 years.
Exclusion criteria: these include a) admission
diagnosis of major trauma, b) need for
therapeutic anticoagulation, c) contraindication
to heparin (allergy or heparin-induced
thrombocytopenia), d) pregnancy,
e) life-support limitation, f) uncontrolled
hypertension (bp > 180/110) for at least
12 hours, g) cerebral hemorrhage/acute
gastrointestinal bleed, h) severe
thrombocytopenia (platelet count <50 ×
109/l), i) International Normalized Ratio (INR)
or activated partial thromboplastin time
(APTT) ≥2 times the upper limit of normal,
j) chronic renal failure or acute-on-chronic
renal failure, and k) initial evaluation more
than 24 hours after commencement of
continuous renal replacement therapy.
Study type Interventional allocation: randomized
Intervention model: double arm
Masking: double blind (subject, relatives,
investigator, outcomes assessor)
Primary purpose: prevention
Date of first enrolment March 2013
Target sample size 266
Recruitment status Recruiting
Primary outcome(s) Venous thromboembolism
Key secondary
outcomes
Catheter-related thrombus, anti-Xa activity,
bleeding, heparin-induced thrombocytopenia,
filter lifespan, length of stay, ventilator free
days, and mortality. We will monitor
neutrophil gelatinase-associated lipocalin
levels and urine volume to determine
whether they can be used as prognostic
factors for renal recovery.
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file 2, and Additional file 3).
All laboratory specimens, reports, data forms, and other
study-related information are identified by a coded number
only. These are stored separately from participant-related
information, both in locked file cabinets in areas with
limited access. The web-based FBI database (Depart-
ment of Health Cooperation and Quality Database Unit,
Region of Southern Denmark, Vejle, Denmark) which
houses the study’s data collection forms is password-
protected. The project principal investigators only have
direct access to their own site’s data sets.
Records of each participant's identity and personal infor-
mation will not be made public. Employees from Good Clin-
ical Practice (GCP), Danish Health andMedicines Authority,
and the corresponding foreign authority will have access to
participants’ medical records and information collected in
connection with the study for quality control (monitoring,
Table 2 Protocol revision chronology
Date Protocol amendment
Original version, 22.02.2011 Amendment Number 1:
Primary reason for amendment:
Changes in the methods sections - a decision to allow the pharmacy at OUH to
generate randomization code was made.
Version 2, 18.05.2011 Amendment Number 2:
Primary reason for amendment:
At the request of GCP changes in the ethics section to elaborate on the procedure for
obtaining consent.
Version 3, 18.07.2012 Amendment Number 3:
Primary reason for amendment:
The methods section was amended to include a description of the conduct of CRRT
during the trial.
Version 4, 25.08.2012 Amendment Number 4:
Primary reason for amendment:
Fleming-Harrington-O’Brien stopping rule and futility measure via ’conditional power’
calculation was introduced.
Version 5, 31.08.2012 Amendment Number 5:
Version 5 was the first version to be submitted to the
Danish Health and Medicines Authority and the Danish
national scientific ethical committee.
Primary reason for amendment:
The comparator dose which was unconfirmed until this point was included in this new
protocol version.
At the request of Danish Health and Medicines Authority changes were made to the
exclusion criteria so that patients with chronic renal failure or acute-on-chronic renal failure
were ineligible. The methods section was also updated to indicate that a patient who
changed from CRRT to intermittent hemodialysis would have reached the end of the study
period. In addition, further details about the reporting of adverse events were included.
Version 6, 21.01.2013 Amendment Number 6:
Primary reason for amendment:
At the request of the Danish national scientific ethical committee a separate
information sheet for the designated surrogates was developed.
The methods section was also revised due to the acquisition of new dialysis machines
at OUH.
Version 7, 06.06.2013 Amendment Number 7:
Primary reason for amendment:
A change in the exclusion criteria:
platelet count of <75× 109/l, changed to <50 × 109/l and INR or APTT ≥1½ times the
upper limit of normal changed to ≥2 times the upper limit of normal.
Issue date: 06 June 2013. Protocol Amendment Number: 07. Authors: Sian Robinson, MB BS; EDIC; Aleksander Zincuk, MD; Ulla Lei Larsen, MD; Claus Ekstrøm, PhD;
Palle Toft, MD, DMSc. OUH, Odense University Hospital; GCP, Good Clinical Practice; CRRT, Continuous renal replacement therapy; APTT, Activated partial
thromboplastin time; INR, International normalized ratio.
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from the sponsor and competing interests and will serve as
a liaison between all three hospitals and the data manager,
ensuring continuity. GCP has direct access to all three sites’
data sets and as such, will work with the data manager to
oversee the intra-study data sharing process. A Data Moni-
toring Committee (DMC) with Bjarne Dahler-Eriksen MD,
PhD as chair (ICU), Torben Bjerregaard Larsen MD,
PhD (centre for thrombosis), Helle Asboe Jørgensen MD,
EDIC (ICU), and Jacob von Bornemann Hjelmborg MSc,
PhD (statistician) has been established. The DMC is inde-
pendent of those conducting, sponsoring, or funding the
FBI trial. The DMC members are required to indicatetheir assent, as well as to declare any competing interests
in the FBI charter. This charter which details the DMC’s
roles and responsibilities, and planned method of func-
tioning is available on request from the FBI study office.
Study participants
Study participants will comprise two groups of critically
ill patients with AKI on CRRT.
Inclusion criteria
Patients are eligible for inclusion if they give consent,
develop AKI, need CRRT, weigh between 45 and 150 kg,
and are more than or equal to 18-years-old.
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These include: a) admission diagnosis of major trauma,
b) need for therapeutic anticoagulation, c) contraindi-
cation to heparin-allergy or HIT, d) pregnancy, e) life-
support limitation, f ) uncontrolled hypertension (blood
pressure >180/110) for at least 12 hours, g) cerebral
hemorrhage or acute gastrointestinal bleeding, h) severe
thrombocytopenia (platelet count <50 × 109/l), i) Inter-
national Normalized Ratio (INR) or activated partial
thromboplastin time (APTT) more than or equal to two
times the upper limit of normal, j) chronic renal failure
or acute-on-chronic renal failure, and k) initial evalu-
ation after more than 24 hours have elapsed from com-
mencement of CRRT.Figure 1 Time schedule of enrolment, interventions, and assessments
leukocytes, CRP, PCT, hematocrit), anti-Xa, and urine and plasma NGAL and
receive sc enoxaparin according to group allocation. Bedside clinical assess
scores, HEME tool) will be conducted, and samples for hematocrit and plat
conducted on the 1st, 3rd and 7th day of inclusion. Once weekly CUS (mo
(measured at 4 hours after enoxaparin dose) and trough anti-Xa (measured
angiography and echocardiography will be performed on clinical suspicion
allocation will be discontinued and participants will receive 40 mg enoxap
according to group allocation will be resumed. Samples of urine and plasm
Activated partial thromboplastin time; anti-Xa, Antifactor Xa; AT, Antithrom
gelatinase-associated lipocalin; Cr, Creatinine; sc, subcutaneous; VTE, Venou
thrombosis; CT, Computed tomography; PE, Pulmonary emboli; CRRT, Cont
daily; HIT, Heparin-induced thrombocytopenia; ICU, Intensive care unit.Randomization
All patients who fulfil the inclusion criteria and who
give consent for participation will be randomized. The
randomization sequence was generated in block sizes of
four by the hospital’s pharmacy at OUH, using a web-
based randomization system. This allocation sequence
is being implemented through use of sequentially num-
bered, opaque, sealed envelopes. Each center will screen
subjects to achieve the enrolment targets demonstrated in
Figure 1. In the event of failure to meet target population,
the study will be expanded to other sites. Allocation
concealment will be ensured as the randomization code
will not be revealed until the patient has been recruited
into the trial.for participants. Routine tests (APTT, platelets, D-dimer, AT,
Cr are measured at baseline. Following randomization, the patient will
ment for VTE and bleeding using validated scoring systems (Well's
elet count will be taken daily. Bilateral lower extremity CUS will be
re frequent if DVT is suspected), as well as samples for peak anti-Xa
at 20 hours after enoxaparin dose) will be taken. Spiral pulmonary CT
of PE. During CRRT-free intervals with CrCl <30 ml/min/1.73 m2, group
arin QD until the CrCl is >30 ml/min/1.73 m2 when enoxaparin dose
a will be taken for NGAL and Cr during CRRT-free intervals. APTT,
bin; CRP, C-reactive protein; PCT, Procalcitonin; NGAL, Neutrophil
s thromboembolism; CUS, Compression ultrasound; DVT, Deep venous
inuous renal replacement therapy; CrCl, Creatinine Clearance; QD, Once
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The medicine module of Critical Information System
(CIS LIVE™; Daintel, Copenhagen, Denmark) used at all
three hospitals allows for blinding. Patients, family mem-
bers, clinicians, research personnel, radiologists, laboratory
technicians, and the trial biostatistician will all be unaware
of study-group assignments. They will remain blinded
until the study database is locked at the end of the trial.
Nurses who administer the drug will be the only party
privy to the actual dose given to each patient as it is im-
possible to prepare an enoxaparin dose of 1 mg/kg be-
forehand. In the event of an emergency (major bleeding,
need for major surgery), a participant’s allocated inter-
vention may be revealed to the attending duty physician
by the nurse providing care for that participant. The actual
allocation will not be disclosed to the patient or study
personnel, and there will be no disclosure of the code in
any of the corresponding patient documents.
Interventions
The intervention for the treatment arm will be 1 mg/kg
enoxaparin sc QD, and the intervention for the control
arm will be 40 mg enoxaparin sc QD. Enoxaparin will
be administered to the thigh or abdomen of the study
patients.
Dispensing
Enoxaparin (Klexane™; Sanofi-Aventis Denmark A/S,
Hørsholm, Denmark) 100 mg/ml is available as prefilled
single-dose syringes containing 40 mg, or as multi-dose
vials containing 300 mg in 3 ml. Nurses will carefully
titrate a dose of 1 mg/kg, using 1 ml or 2 ml syringes as
needed.
Modifications
Project medicine will be adjusted in several situations.
If creatinine-clearance (CrCl) is <30 ml/min/1.73 m2
during CRRT-free intervals, group allocation will be
discontinued and participants will receive 40 mg QD.
Once CrCl is >30 ml/min/1.73 m2, group allocation
will be resumed. In the event of VTE, group allocation
will be discontinued, and patients will receive a full
treatment dose of enoxaparin. Enoxaparin will be tem-
porarily discontinued in the case of oozing, and packed
red blood cells, fresh frozen plasma, and protamine
sulphate may be administered at the discretion of the
attending physician. Enoxaparin will be resumed accord-
ing to the group allocation when oozing is no longer ob-
served. Should the platelet count decrease to less than
50 × 109/L, or if there is an unexplained platelet count
decrease to less than 50% of baseline, or other suspicion
of HIT, enoxaparin will be stopped and mechanical
prophylaxis or the HIT-safe anticoagulant, argatroban
(Novastan™; Swedish Orphan Biovitrum A/S, Lyngby,Denmark), will be started. The patient will be evaluated
by the 4 T’s clinical scoring system [18] and blood samples
will be taken for PF4/heparin enzyme-linked immunosorb-
ent assay (ELISA) and 14C-platelet serotonin release assay.
Adherence
To ensure protocol adherence and data quality, research
coordinators attended study-specific training sessions.
Throughout the trial participating centers will also edu-
cate rotating ICU residents and hold periodic updates
for nurses. GCP monitoring will also serve to improve
protocol adherence.
All the research physicians who will perform interven-
tions on participants are trained in anaesthesia and in-
tensive care, and as such have great experience with
using ultrasound. In addition, all investigators received
specific training in the performance of venous compres-
sion ultrasound (CUS) of the under extremities. The
majority of these physicians also have prior training in
Focused Assessed Transthoracic Echocardiography (FATE).
All other aspects of care and management of trial out-
comes are at the ICU team’s discretion.
Adverse events
All serious adverse events will be immediately reported
to the sponsor. The immediate reports will be followed
within 24 hours by detailed written reports (please see
Additional file 4). The investigator will also comply with
the regulatory requirements related to the reporting of un-
expected serious adverse drug reactions to the Danish na-
tional scientific ethical committee and the Danish Health
and Medicines Authority.
The sponsor will expedite the reporting of all adverse
drug reactions that are both serious and unexpected to
all concerned investigators and/or institutions, the Da-
nish national scientific ethical committee and the Danish
Health and Medicines Authority within the timeframe
specified by these authorities.
The sponsor will submit to the regulatory authorities
all safety updates as required by these regulatory bodies.
The following will not be reported: symptoms related to
the patient’s underlying disease (such as fatigue, diarrhoea,
pain, nausea, or vomiting), delirium, electrolyte imbalance,
and death that ensues because of withdrawal of active
treatment.
Outcome measures
The primary outcome is the occurrence of proximal leg
DVT detected 3 days or more after randomization or
pulmonary embolism (PE) diagnosed on computed tom-
ography scan (CT) of the chest or at autopsy (for defini-
tions of outcome measures please see Additional file 5).
Secondary outcomes include all other DVTs, catheter-
related thrombus, anti-Xa activity, bleeding, HIT, filter
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In addition, we will monitor NGAL levels and urine vol-
ume to determine whether they can be used as prognostic
factors for renal recovery.
Study conduct
This trial is active and enrolment began in March 2013,
and will continue until March 2015. The study scheme
is outlined in Figure 1. For details on the conduct of CRRT
please see Additional file 6. We will record admission
diagnosis, ICU severity of illness scores, and baseline
demographic data for both groups of participants.
Examination and blood tests
Anti-Xa, activated partial thromboplastin time (APTT),
platelets, D-dimer, antithrombin (AT), leukocytes, c-
reactive protein (CRP), procalcitonin (PCT), hematocrit,
urine and plasma NGAL, urine and plasma creatinine (Cr)
are all measured at baseline. Peak and trough anti-Xa will
be measured on day three, and once weekly. We will record
the urine output prior to discontinuation of dialysis, and
measure NGAL and Cr during CRRT-free intervals. All pa-
tients will have daily hematocrit and platelet count mea-
sured during the study period. Other parameters will be
measured as per the departments’ norm. Samples for anti-
Xa activity will be analyzed in a blinded fashion using a
validated chromogenic assay kit (COAMATIC Heparin,
Chromogenix, Instrumentation Laboratory Company,
Lexington, Kentucky, United States). NGAL in urine and
plasma will be quantified by particle-enhanced turbidi-
metric immunoassay (NGAL Test™, Roche Modular P
apparatus, BioPorto Diagnostics A/S, Gentofte, Denmark)
according to the manufacturer’s instructions.
Patients will undergo daily bedside clinical assessment
for bleeding or VTE using validated tools for the ICU
population [11,19,20]. Bilateral lower extremity CUS at
1-cm intervals from the iliac/common femoral vein to
the popliteal vein will be conducted on the first, third,
and seventh day of inclusion. CUS will then be repeated
on a weekly basis (more frequently if DVT is clinically
suspected). All positive CUS will be verified by a radiolo-
gist. Serial ultrasound examinations will be terminated if
a positive study for DVT is obtained. Spiral pulmonary
CT angiography and echocardiography will be performed
on clinical suspicion of PE.
Patients will be followed until one of the following
occurs: a combination of VTE and renal recovery, a
combination of HIT and renal recovery, ICU death or
discharge, or a change from continuous to intermittent
dialysis.
Sample size and statistical methods
We hypothesized that the optimal dose of enoxaparin
would reduce the incidence of VTE in critically ill AKIpatients requiring CRRT without causing an increase in
bleeding. An additional hypothesis was that high urine
output prior to the discontinuation of dialysis and low
NGAL in dialysis-free intervals can predict renal recov-
ery in these patients.
We estimated that with 133 patients in each group the
study would have 80% power to show a 40% reduction
in the relative risk of VTE with 1 mg/kg enoxaparin sc
QD, assuming an incidence rate of 40% in the control
group, at a two-sided alpha level of 0.05. An interim
analysis (for both safety and efficacy) after approximately
50% of the patients have completed the study will be
performed by an independent statistician blinded to the
treatment allocation. These outcomes will be analyzed
with stopping rules based on the Fleming-Harrington-
O’Brien stopping boundary using P = 0.01, with adjust-
ment for an overall type 1 error of 0.05, and with the
final analysis conducted at P = 0.045 [21]. The statistician
will report, in strict confidence, to the DMC (see Table 3).
The DMC members will not be blinded to patient alloca-
tion. They may request other analyses (such as data from
other comparable trials) prior to reaching a decision on
the continuation of the trial. The DMC will report its rec-
ommendations in writing to the Trial Steering Committee.
The study can also be terminated if the difference between
groups is negligible and the statistician using ’conditional
power’ calculation determines that continuation will be
futile.
We will analyze data from all randomized patients
according to their assigned group (intention-to-treat
principle). We will use either estimating-equation methods
or continuous repeated measures (a statistical model) in
the event of missing data. All baseline demographic
values for these two groups will be compared, using the
Student’s t-test or Mann-Whitney rank sum test for
continuous variables and chi-squared (χ2) or Fisher's
exact test for categorical variables.
The primary outcome VTE will be compared between
the two groups. Four pre-specified subgroup analyses
based on: 1) the patient's ICU admission (surgical versus
medical), 2) center experience, 3) presence or absence of
edema, and 4) presence or absence of vasopressor or
inotropes use will be performed.
Multiple regression analysis will conducted to evaluate:
1) the influence of vasopressor, respiratory support, co-
morbidity, organ dysfunction scores, and CrCl on the in-
cidence of VTE and bleeding between groups; and 2) to
examine the relationship between biomarker, demographic
variables, comorbidity, and Acute Kidney Injury Network
classification.
The prediction ability of urine output and NGAL for
successful discontinuation of CRRT will be assessed with
the area under the receiver operating characteristic
(ROC) curve method. Anti-Xa levels will be analyzed by
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calculate hazard ratios and associated 95% confidence
intervals using Cox regression analysis and the Kaplan-
Meier method with log-rank testing.
Discussion
LMWHs at standard doses appear to protect ward pa-
tients against VTE, but what is less clear is the optimal
dose suitable for ICU patients. ICU patients with AKI
present a particular challenge because of their increased
risk of bleeding and thrombosis. Existing guidelines in
Denmark recommend 40 mg enoxaparin for thrombopro-
phylaxis, but this is thought to be inadequate. A previous
pharmacokinetic trial suggested that a dose of 1 mg/kg
enoxaparin may offer optimal thromboprophylaxis [17].
Our current study aims to confirm 1 mg/kg enoxaparin is
the optimal dose in this high-risk population. As the
study design is one of a randomized double-blinded
multicenter trial, it should be considered a high quality
trial aiming to provide class I evidence of the primary
endpoint.So far, only one type of LMWH (dalteparin) has won
approval for use in patients with severe renal insuffi-
ciency [22]. Critically ill patients have decreased levels
of protein, and thus a larger free fraction of enoxa-
parin. The volume of distribution of enoxaparin is
only 5 L and this, coupled with a small molecular
weight, allow for normal dosing as the drug would be
expected to be cleared by the high volumes of fluid
employed in hemofiltration. Thus, our study has im-
plications for clinical practice as our findings may
challenge the premise that selected LMWHs should
be avoided in such patients.
Finally, there are currently no established guidelines
for the discontinuation of dialysis. We seek to use a
combination of a clinical indicator (urine volume) and
a biomarker (NGAL) to predict renal recovery.Trial status
This trial is active. Enrolment began in March 2013 and
will continue for two years.
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